Medications to Reduce
the Potential for Harm
Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders.
Our Technology is Designed to Resist Manipulation for Snorting and Provide Barriers to Injection
Our lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine designed to deter attempts to crush and snort and provides barriers to injection.